|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luu C, Arrington AK, Schoellhammer HF,
Singh G and Kim J: Targeted therapies in colorectal cancer:
surgical considerations. J Gastrointest Oncol. 4:328–336.
2013.PubMed/NCBI
|
|
3
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells - perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhong Z, Wen Z and Darnell JE Jr: Stat3: A
STAT family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirano T, Ishihara K and Hibi M: Roles of
STAT3 in mediating the cell growth, differentiation and survival
signals relayed through the IL-6 family of cytokine receptors.
Oncogene. 19:2548–2556. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Turkson J and Jove R: STAT proteins: Novel
molecular targets for cancer drug discovery. Oncogene.
19:6613–6626. 2000. View Article : Google Scholar
|
|
7
|
Azare J, Doane A, Leslie K, Chang Q,
Berishaj M, Nnoli J, Mark K, Al-Ahmadie H, Gerald W, Hassimi M, et
al: Stat3 mediates expression of autotaxin in breast cancer. PLoS
One. 6:e278512011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dauer DJ, Ferraro B, Song L, Yu B, Mora L,
Buettner R, Enkemann S, Jove R and Haura EB: Stat3 regulates genes
common to both wound healing and cancer. Oncogene. 24:3397–3408.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tseng LM, Huang PI, Chen YR, Chen YC, Chou
YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, et al: Targeting
signal transducer and activator of transcription 3 pathway by
cucurbit-acin I diminishes self-renewing and radiochemoresistant
abilities in thyroid cancer-derived CD133+ cells. J
Pharmacol Exp Ther. 341:410–423. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chan KS, Sano S, Kiguchi K, Anders J,
Komazawa N, Takeda J and DiGiovanni J: Disruption of Stat3 reveals
a critical role in both the initiation and the promotion stages of
epithelial carcinogenesis. J Clin Invest. 114:720–728. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bertorelle R, Rampazzo E, Pucciarelli S,
Nitti D and De Rossi A: Telomeres, telomerase and colorectal
cancer. World J Gastroenterol. 20:1940–1950. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tatsumoto N, Hiyama E, Murakami Y, Imamura
Y, Shay JW, Matsuura Y and Yokoyama T: High telomerase activity is
an independent prognostic indicator of poor outcome in colorectal
cancer. Clin Cancer Res. 6:2696–2701. 2000.PubMed/NCBI
|
|
13
|
Liu Z, Li Q, Li K, Chen L, Li W, Hou M,
Liu T, Yang J, Lindvall C, Björkholm M, et al: Telomerase reverse
transcriptase promotes epithelial-mesenchymal transition and stem
cell-like traits in cancer cells. Oncogene. 32:4203–4213. 2013.
View Article : Google Scholar
|
|
14
|
Brown J, O'Prey J and Harrison PR:
Enhanced sensitivity of human oral tumours to the flavonol, morin,
during cancer progression: Involvement of the Akt and stress kinase
pathways. Carcinogenesis. 24:171–177. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Manna SK, Aggarwal RS, Sethi G, Aggarwal
BB and Ramesh GT: Morin (3,5,7,2′,4′-Pentahydroxyflavone) abolishes
nuclear factor-kappaB activation induced by various carcinogens and
inflammatory stimuli, leading to suppression of nuclear
factor-kappaB-regulated gene expression and up-regulation of
apoptosis. Clin Cancer Res. 13:2290–2297. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gupta SC, Phromnoi K and Aggarwal BB:
Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells
through activation of protein tyrosine phosphatase SHP1. Biochem
Pharmacol. 85:898–912. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seimiya H, Oh-hara T, Suzuki T, Naasani I,
Shimazaki T, Tsuchiya K and Tsuruo T: Telomere shortening and
growth inhibition of human cancer cells by novel synthetic
telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer
Ther. 1:657–665. 2002.PubMed/NCBI
|
|
18
|
Serrano D, Bleau AM, Fernandez-Garcia I,
Fernandez-Marcelo T, Iniesta P, Ortiz-de-Solorzano C and Calvo A:
Inhibition of telomerase activity preferentially targets aldehyde
dehydrogenase-positive cancer stem-like cells in lung cancer. Mol
Cancer. 10:962011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chung SS, Aroh C and Vadgama JV:
Constitutive activation of STAT3 signaling regulates hTERT and
promotes stem cell-like traits in human breast cancer cells. PLoS
One. 8:e839712013. View Article : Google Scholar
|
|
20
|
Park JI, Venteicher AS, Hong JY, Choi J,
Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, et al:
Telomerase modulates Wnt signalling by association with target gene
chromatin. Nature. 460:66–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hoffmeyer K, Raggioli A, Rudloff S, Anton
R, Hierholzer A, Del Valle I, Hein K, Vogt R and Kemler R:
Wnt/β-catenin signaling regulates telomerase in stem cells and
cancer cells. Science. 336:1549–1554. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Korsmeyer SJ: BCL-2 gene family and the
regulation of programmed cell death. Cancer Res. 59(Suppl):
S1693–S1700. 1999.
|
|
23
|
Kern SE, Kinzler KW, Bruskin A, Jarosz D,
Friedman P, Prives C and Vogelstein B: Identification of p53 as a
sequence-specific DNA-binding protein. Science. 252:1708–1711.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abraham RT: Cell cycle checkpoint
signaling through the ATM and ATR kinases. Genes Dev. 15:2177–2196.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi K, Shirakabe K, Shibuya H, Irie
K, Oishi I, Ueno N, Taniguchi T, Nishida E and Matsumoto K:
Identification of a member of the MAPKKK family as a potential
mediator of TGF-beta signal transduction. Science. 270:2008–2011.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tibbles LA and Woodgett JR: The
stress-activated protein kinase pathways. Cell Mol Life Sci.
55:1230–1254. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alnemri ES, Livingston DJ, Nicholson DW,
Salvesen G, Thornberry NA, Wong WW and Yuan J: Human ICE/CED-3
protease nomenclature. Cell. 87:1711996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jacobs MD and Harrison SC: Structure of an
IkappaBalpha/NF-kappaB complex. Cell. 95:749–758. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bracht K, Nicholls AM, Liu Y and Bodmer
WF: 5-Fluorouracil response in a large panel of colorectal cancer
cell lines is associated with mismatch repair deficiency. Br J
Cancer. 103:340–346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garcia R, Bowman TL, Niu G, Yu H, Minton
S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et
al: Constitutive activation of Stat3 by the Src and JAK tyrosine
kinases participates in growth regulation of human breast carcinoma
cells. Oncogene. 20:2499–2513. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takemoto S, Ushijima K, Kawano K,
Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M,
Kakuma T, et al: Expression of activated signal transducer and
activator of transcription-3 predicts poor prognosis in cervical
squamous-cell carcinoma. Br J Cancer. 101:967–972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang X, Wang G, Zhao Y, Liu X, Ding Q, Shi
J, Ding Y and Wang S: STAT3 mediates resistance of
CD44(+)CD24(−/low) breast cancer stem cells to tamoxifen in vitro.
J Biomed Res. 26:325–335. 2012. View Article : Google Scholar
|
|
33
|
Fang SH, Hou YC, Chang WC, Hsiu SL, Chao
PD and Chiang BL: Morin sulfates/glucuronides exert
anti-inflammatory activity on activated macrophages and decreased
the incidence of septic shock. Life Sci. 74:743–756. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hsiang CY, Wu SL and Ho TY: Morin inhibits
12-O-tetradecanoyl-phorbol-13-acetate-induced hepatocellular
transformation via activator protein 1 signaling pathway and cell
cycle progression. Biochem Pharmacol. 69:1603–1611. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sreedharan V, Venkatachalam KK and
Namasivayam N: Effect of morin on tissue lipid peroxidation and
antioxidant status in 1, 2-dimethylhydrazine induced experimental
colon carcinogenesis. Invest New Drugs. 27:21–30. 2009. View Article : Google Scholar
|
|
36
|
Gurung RL, Lim SN, Low GK and Hande MP:
MST-312 alters telomere dynamics, gene expression profiles and
growth in human breast cancer cells. J Nutrigenet Nutrigenomics.
7:283–298. 2014. View Article : Google Scholar
|
